Breast cancer is one of the most common neoplasms among women. Anticancer strategies using natural formulations and phytotherapies are promising antitumor treatment alternatives. This review assesses the antitumor effects of curcumin on breast cancer reported in preclinical in vitro and in vivo animal models. We used five databases to search for preclinical studies published up to May 2021. The assessments included the effects of curcumin on the proliferation, viability, and apoptosis of breast cancer cell lineages and on tumor volume. In total, 60 articles met the inclusion criteria. Curcumin administered at different concentrations and via different routes of administration inhibited proliferation, decreased viability, and induced apoptosis in human and animal breast cancer cells. Nanoparticle formulations of curcumin administered orally, via implant, and intraperitoneally reduced the tumor volume of human and murine mammary cells in vivo. Moreover, curcumin nanoformulations exert positive effects on tumor growth inhibition in animal models of breast cancer. Further randomized clinical trials are warranted to assess the efficacy and safety of curcumin formulations for clinical use.

This study aimed to examine the prevalence rates of poor quality sleep and daytime sleepiness in health professionals and their association with socioeconomic, lifestyle, and anthropometric factors and psychosocial work conditions. This cross-sectional study was performed with health professionals from various public and private hospitals in Rio Verde, Goiás, Brazil. Daytime sleepiness and sleep quality were assessed using the Epworth Sleepiness Scale and the Pittsburgh Sleep Quality Index, respectively. The variables were analyzed using multiple hierarchical Poisson regression in the statistical package Stata version 13.0. A total of 244 health professionals participated in this study (women, 78.28%). The rates of abnormal daytime sleepiness and poor sleep quality were 50.41% (n = 123) and 55.74% (n = 136), respectively. Reduced physical activity was associated with poor sleep quality (prevalence ratio (PR) = 1.32; 95% confidence interval (CI) 1.02–1.70, p = 0.035). Age between 20 and 29 years (PR = 2.59; 95% CI 1.37–4.91, p = 0.021) and 30 and 49 years (PR = 2.09; 95% CI 1.12–3.91, p = 0.021), as well as excessive alcohol consumption (PR = 1.29; 95% CI 1.01–1.66, p = 0.048), were risk factors for daytime sleepiness. Conversely, adequate bodyweight (PR = 0.52; 95% CI 0.33–0.82, p = 0.005) was considered a protective factor. The present findings suggest high rates of abnormal daytime sleepiness and poor sleep quality among healthcare professionals. We emphasize the importance of physical activity, adequate weight, and healthy habits for better quality sleep and reduced daytime sleepiness.

Introduction: COVID-19 is a disease caused by the new coronavirus, called SARS-CoV-2, an RNA virus, which initially emerged in Wuhan, China, in December 2019. asymptomatic and severe conditions, especially in patients with previous pathologies, such as patients with rheumatologic diseases. Method: The work was carried out in the form of an integrative review of the literature, it aimed to bring together the studies and identify the possible complications that rheumatic diseases would have in patients who contract COVID-19. Results/Discurssion: In view of the current health situation, the analysis of the studies showed that both COVID-19 and rheumatic diseases present a pathogenic cytokine, among the diseases rheumatoid arthritis, lupus erythematosus and primary Sjogren's spindrome. Conclusion: The work presented difficulties during its production, the greatest difficulty was the lack of literature that addresses the subject. Therefore, patients with DRIM must be evaluated individually and dimensioned for each clinical situation, especially in situations where COVID is suspected, in these cases the rheumatologist has a fundamental role in decision-making.

A Vasculite por imunoglobulina A (IgAV) é conhecida por ser uma vasculite sistêmica de pequenos vasos. Apesar desta condição ser capaz de se estabelecer em qualquer faixa etária, o perfil epidemiológico desta doença afeta, majoritariamente, a população pediátrica situada entre 2 e 10 anos de idade. Nesse sentido, este artigo descritivo, tem como objetivo relatar o raro caso de uma paciente adulta que evoluiu com a IgAV, apresentação de forma cutânea, sendo tratada com corticosteroide. Para tanto, após consentimento livre e esclarecido da paciente foi aprovado pelo Comitê de Ética em Pesquisa da Universidade de Rio Verde (UniRV – GO), cujo Certificado de Apresentação para Apreciação Ética é 36621920.0.0000.507. Logo, descobriu-se que a paciente evoluiu com clínica compatível para IgAV de provável acometimento cutâneo pelas lesões em forma de púrpura e pelo envolvimento renal, apresentando boa resposta terapêutica com a corticoterapia em doses não imunossupressoras e após 1 ano e 3 meses de follow-up houve remissão do quadro sem novos episódios. Encontra-se na literatura alguns relatos sobre a boa resposta terapêutica desta forma clínica com a corticoterapia em doses não imunossupressoras, no entanto ensaios clínicos são necessários.

Objective: To evaluate the prevalence of poor sleep quality and identify its associated factors among third-trimester pregnant women attending a public healthcare service in a municipality in Goiás, Brazil. Methods: This was a cross-sectional, analytical, and epidemiological study conducted with a probabilistic sample of 243 pregnant women. Sleep quality was assessed using the Pittsburgh Sleep Quality Index (PSQI), along with sociodemographic, behavioral, health, sexual, and pregnancy-related variables. Data were analyzed using Poisson regression with robust variance to estimate prevalence ratios (PR) and their respective 95% confidence intervals (95% CI), with a significance level of 5% ( p < 0.05). Results: The prevalence of poor sleep quality was 24.7%. Multivariate analysis identified non-white race/color (PR = 4.30; 95% CI 1.48–12.56), unemployment (PR = 3.07; 95%CI 1.23–7.63), and not engaging in physical activity (PR = 3.28; 95% CI 1.37–7.83) as independent predictors of poor sleep quality. Additionally, excessive daytime sleepiness (PR = 3.48; 95% CI 1.55–7.82) and high risk of stress (PR = 2.71; 95% CI 1.09–6.75) were also significantly associated with the outcome. Conclusion: Poor sleep quality is a highly prevalent issue in the studied population and is strongly associated with sociodemographic and behavioral factors. These findings highlight the importance of integrating into prenatal care interventions that address the social determinants of health.